Skip to main content
2025 STS Annual Meeting Main banner
Back

Industry Symposium

Mastering the Integration of Immunotherapy in Resectable NSCLC: Practical Considerations for Real-World Practice

Saturday, January 25, 2025
5:45pm – 6:45pm PT
Location: JW Marriott LA Live, Gold Ballroom 3

    Industry Speaker(s)

  • Stephen Broderick, MD, MPHS

    Associate Professor of Surgery
    Johns Hopkins Medical Institutions
    Baltimore, Maryland, United States

    Disclosure(s): Astrazeneca: Advisory Board (Terminated, February 1, 2024); Bristol Meyers Squibb: Advisory Board (Ongoing), Consultant (Ongoing)

  • Jessica S. Donington, MD (she/her/hers)

    Chief Thoracic Surgery
    University of Chicago
    Chicago, Illinois, United States

    Disclosure(s): Amgen: Advisory Board (Ongoing); Astra Zeneca global: Advisory Board (Ongoing), Speaker (Ongoing); BMS: Advisory Board (Ongoing), Speaker (Ongoing); Merck: Advisory Board (Ongoing), Speaker (Ongoing); Roche Genentech: Advisory Board (Ongoing), Speaker (Ongoing)

  • Sandip Patel, MD

    Professor
    UC San Diego
    Del Mar, California, United States

    Disclosure(s): Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Certis, Eli Lilly, Jazz, Genentech, Illumina , Merck, Pfizer, Signatera, Tempus: Advisory Board (Terminated); Amgen, AstraZeneca, A2bio, Bristol-Myers Squibb, Eli Lilly, Fate Therapeutics, Gilead, Iovance, Merck, Pfizer, Roche/Genentech: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated)

Disclosure(s):
Stephen Broderick, MD, MPHS: Astrazeneca: Advisory Board (Terminated, February 1, 2024); Bristol Meyers Squibb: Advisory Board (Ongoing), Consultant (Ongoing)
Jessica S. Donington, MD: Amgen: Advisory Board (Ongoing); Astra Zeneca global: Advisory Board (Ongoing), Speaker (Ongoing); BMS: Advisory Board (Ongoing), Speaker (Ongoing); Merck: Advisory Board (Ongoing), Speaker (Ongoing); Roche Genentech: Advisory Board (Ongoing), Speaker (Ongoing)
Sandip Patel, MD: Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Certis, Eli Lilly, Jazz, Genentech, Illumina , Merck, Pfizer, Signatera, Tempus: Advisory Board (Terminated); Amgen, AstraZeneca, A2bio, Bristol-Myers Squibb, Eli Lilly, Fate Therapeutics, Gilead, Iovance, Merck, Pfizer, Roche/Genentech: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated)